Special Considerations for Advanced Heart Failure Surgeries: Durable Left Ventricular Devices and Heart Transplantation.
Armaan Fazal AkbarAlice L ZhouAnnie WangAmy S N FengAlexandra A RizaldiJessica M RuckAhmet KılıçPublished in: Journal of cardiovascular development and disease (2024)
Heart transplantation and durable left ventricular assist devices (LVADs) represent two definitive therapies for end-stage heart failure in the modern era. Despite technological advances, both treatment modalities continue to experience unique risks that impact surgical and perioperative decision-making. Here, we review special populations and factors that impact risk in LVAD and heart transplant surgery and examine critical decisions in the management of these patients. As both heart transplantation and the use of durable LVADs as destination therapy continue to increase, these considerations will be of increasing relevance in managing advanced heart failure and improving outcomes.
Keyphrases
- heart failure
- left ventricular
- cardiac resynchronization therapy
- end stage renal disease
- decision making
- ejection fraction
- acute heart failure
- aortic stenosis
- newly diagnosed
- hypertrophic cardiomyopathy
- atrial fibrillation
- acute myocardial infarction
- minimally invasive
- chronic kidney disease
- left atrial
- coronary artery bypass
- stem cells
- squamous cell carcinoma
- peritoneal dialysis
- metabolic syndrome
- acute coronary syndrome
- mesenchymal stem cells
- risk assessment
- weight loss
- adipose tissue
- smoking cessation
- transcatheter aortic valve replacement